Harpoon Therapeutics Inc (DELISTED) (HARP:DL)
23.01
0.00 (0.00%)
USD |
NASDAQ |
Mar 11, 16:00
Harpoon Therapeutics Revenue (Quarterly): 4.448M for Sept. 30, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 4.448M |
| June 30, 2023 | 20.22M |
| March 31, 2023 | 8.583M |
| December 31, 2022 | 4.089M |
| September 30, 2022 | 13.62M |
| June 30, 2022 | 8.303M |
| March 31, 2022 | 5.906M |
| December 31, 2021 | 4.325M |
| September 30, 2021 | 4.484M |
| June 30, 2021 | 5.838M |
| March 31, 2021 | 9.007M |
| December 31, 2020 | 7.492M |
| Date | Value |
|---|---|
| September 30, 2020 | 3.893M |
| June 30, 2020 | 2.762M |
| March 31, 2020 | 3.297M |
| December 31, 2019 | 2.234M |
| September 30, 2019 | 1.417M |
| June 30, 2019 | 1.063M |
| March 31, 2019 | 1.063M |
| December 31, 2018 | 1.061M |
| September 30, 2018 | 1.063M |
| June 30, 2018 | 1.063M |
| March 31, 2018 | 1.563M |
| December 31, 2017 | 0.708M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.234M
Minimum
Dec 2019
20.22M
Maximum
Jun 2023
6.781M
Average
5.161M
Median
Revenue (Quarterly) Benchmarks
| Merck & Co Inc | 16.66B |
| Axonics Inc | 116.19M |
| Johnson & Johnson | 22.47B |
| Boston Scientific Corp | 4.209B |
| Ambrx Biopharma Inc (DELISTED) | 0.053M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.802M |
| Total Expenses (Quarterly) | 16.59M |
| EPS Diluted (Quarterly) | -0.46 |
| Enterprise Value | 460.74M |
| Profit Margin (Quarterly) | -40.51% |
| Earnings Yield | -38.07% |
| Normalized Earnings Yield | -36.51 |